Biochemical Role of Long Non-coding RNA MALAT 1 and Serum Tumor Necrosis Factor Alpha in Bronchial Asthma Patients.

Sohag University

Status: Completed

Conditions: Bronchial Asthma

Treatments: Diagnostic Test: Long non-coding MALAT1 gene expression assay:

Study type: Observational

Funder types: Other

Identifiers

NCT06459895

Soh-Med-24-05-03PD

Details and patient eligibility

About

Bronchial asthma affects more than a quarter of a billion people worldwide. It is responsible for over 1000 deaths a day, of which the majority are preventable (Levy, 2015).

Asthma is a common heterogeneous disease characterized by chronic airway inflammation. It is defined by the history of variable respiratory symptoms, such as shortness of breath, chest tightness, wheezes, and cough, together with variable expiratory airflow limitation. Airflow limitation may later become persistent (GINA, 2023).

The diagnosis of asthma is based on the history of these characteristic symptoms and evidence of variable expiratory airflow limitation from bronchodilator reversibility testing or other tests (GINA, 2023).

Enrollment: 194 patients

Sex: All

Ages: 15 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All patients were admitted to Sohag University Hospital, chest department DIAGNOSED AS BRONCHIAL ASTHMA

Exclusion criteria

• Patients with malignancies, major trauma or surgery, and acute or chronic infectious diseases were excluded.

Trial design

194 participants in 2 patient groups

diseased group

Description:

bronchial asthma diseased group

Treatment:

Diagnostic Test: Long non-coding MALAT1 gene expression assay:

control group

Description:

healthy person

Treatment:

Diagnostic Test: Long non-coding MALAT1 gene expression assay: